Odiparcil

DB06609InvestigationalSmall molecule

Investigated for use/treatment in atrial fibrillation, cardiovascular disorders, thrombosis, and venous thromboembolism.

Chemical structure of Odiparcil
Primary indication
Investigated for use/treatment in atrial fibrillation, cardiovascular disorders, thrombosis, and venous thromboembolism.Curator reviewed
Formula / weight
C15H16O6S · 324.35 g/mol (avg)
Code names
424323

Resolves to

Compound
UNIIFIK1414ZI8CAS137215-12-4ChEMBLCHEMBL2107763
Structure
InChIKeyJRHNIQQUVJOPQC-AQNFWKISSA-NSMILES[H][C@@]1(O)CS[C@@]([H])(OC2=CC3=C(C=C2)C(C)=CC(=O)O3)[C@]([H])(O)[C@@]1([H])O
Targets
P00734F2

What you can answer from here — as of January 29, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
4Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1+ReferenceStructured and connected to the statements they support
Sign in

Which drugs share a target with Odiparcil, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In